Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mantovani, L.G.
Right arrow Articles by Szucs, T.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mantovani, L.G.
Right arrow Articles by Szucs, T.D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 4, 953-958, April 1999
© 1999 European Society of Human Reproduction and Embryology

Pharmaco-economic aspects of in-vitro fertilization in Italy

L.G. Mantovani1, A. Belisari and T.D. Szucs

Center of Pharmacoeconomics, Institute of Pharmacological Sciences, University of Milan, Via Balzaretti 9, I-20133, Milan

Given the higher efficacy of follitropin-beta, a new recombinant follicle stimulating hormone (r-FSH), versus urinary-FSH (u-FSH), the present study was carried out to evaluate the cost-effectiveness ratio (CER) of follitropin-beta in comparison with u-FSH in women undergoing in-vitro fertilization (IVF) in Italy. Clinical decision analysis techniques were used to retrospectively model the direct medical costs of women undergoing IVF treatment. Seven Italian experts were interviewed, using a semi-structured questionnaire, in order to adapt the results of all clinical trials to the Italian patterns of care. Three analyses were conducted considering the public, the private sectors and a mixture of them (currently representing the Italian situation). The estimated total cost of IVF treatments varies from 106.9 and 211.7 billion Lire (63.2 and 125.2 million US$) depending on setting and type of treatment. The average CER varies from 21.5 and 37.7 million Lire (12 700 and 22 300 $US) in the different hypotheses considered. The incremental CER varies from 19.2 and 26.0 million Lire (11 300 and 15 400 $US) depending on setting and type of treatment.

Key words: costs/cost-effectiveness analysis/in-vitro fertilization/Italy/recombinant FSH

1 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
L. Garceau, J. Henderson, L.J. Davis, S. Petrou, L.R. Henderson, E. McVeigh, D.H. Barlow, and L.L. Davidson
Economic implications of assisted reproductive techniques: a systematic review
Hum. Reprod., December 1, 2002; 17(12): 3090 - 3109.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.E.F. Zwart-van Rijkom, F.J. Broekmans, and H.G.M. Leufkens
From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study
Hum. Reprod., April 1, 2002; 17(4): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Sykes, H. J. Out, S. J. Palmer, and J. v. Loon
The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments
Hum. Reprod., December 1, 2001; 16(12): 2557 - 2562.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Daya, W. Ledger, J.P. Auray, G. Duru, K. Silverberg, M. Wikland, R. Bouzayen, C.M. Howles, and A. Beresniak
Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK
Hum. Reprod., December 1, 2001; 16(12): 2563 - 2569.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.